• Brand Introduction:

    As a category B drug, it has been included in the National Reimbursement Drug List (NRDL). With the level I medical evidence, it is the first anti-hepatic fibrosis therapeutic drug recommended in the Six Major Guidelines/Consensuses, and also the first Chinese patent drug for treatment of hepatopathy for which Phase II clinical trials have been completed in the United States upon approval by the FDA. Substantial clinical evidences show that Fuzhenghuayu has the efficacy of preventing and treating hepatic fibrosis and liver cirrhosis, and reducing the risk of liver cancer.


The information on this page is only for drug information introduction, not for drug advertisement. For detailed prescription information, please refer to the latest version approved by NMPA. The product information on this website should not be used as a substitute for medical advice and medical consultation provided by a physician or other qualified medical professional and should not be used for the diagnosis of a disease. Please click OK to enter.